Pacifico Biolabs Raises €7M to Turn Germany’s Idle Breweries into Alternative Protein Factories

• Capital expenditure: Avoiding new-build fermentation facilities removes tens of millions in upfront costs .
• Speed to production: Retrofitting takes far less time than constructing a greenfield plant .

The company claims this model puts it on a path to price parity with conventional meat—a milestone that has remained elusive for many precision-fermentation competitors .

Series A Investors

The round was led by Stray Dog Capital. Other participants included:

• Technologiegründerfonds Sachsen (TGFS)
• Sprout & About Ventures
• Simon Capital
• FoodLabs
• An undisclosed regional brewery partner

This follows earlier raises: a $3.3 million pre-seed round in early 2024 (co-led by Simon Capital and FoodLabs) and €680,000 in public funding secured in 2025 .

Why It Matters: Domestic Protein and Supply-Chain Resilience

Europe imports roughly 70% of its protein for animal feed—primarily soy from South America—creating both a large carbon footprint and a strategic vulnerability . Pacifico Biolabs frames its mycelium protein as a domestically produced alternative that reduces that import dependence.

By tapping underutilized industrial infrastructure, the company also sidesteps the land-use and agricultural constraints that limit plant-based protein scalability in Europe .

Scaling Plans and Product Roadmap

The Series A funds are directed toward three main areas:

• Production scale-up in Saxony, Germany, targeting an output of 200 tonnes per month.
• Team expansion across fermentation science, engineering, and commercial roles .
• Commercial launches in the DACH region (Germany, Austria, Switzerland) and Nordic Europe, with products expected to reach retail shelves via brand and retailer partners by late 2026 .

The company is initially focused on whole-cut meat alternatives—primarily beef and poultry formats—though earlier development work also explored seafood analogues using the same mycelium platform .

Pacifico Biolabs' brewery-retrofit strategy may offer a blueprint for other fermentation startups facing the same capital-intensity problem. Whether the model proves economically viable at scale will depend on execution in Saxony and the consumer reception when products hit shelves later this year.